Evidence map›Paper›PMID 42548704›Full record

ArticleFrontiers in immunology2026

Conformational bias in SARS-CoV-2 Spike CD4+ T-cell epitope dominance.

Samuel J Landry, N Kalaya Steede, Yali Tiomkin, Haley Smith, Ramgopal R Mettu, Loren Gragert, Judith H Aberle, Kevin J Zwezdaryk, Crystal Zheng, Jay K Kolls and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Samuel J LandryDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
N Kalaya SteedeDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
Yali TiomkinDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
Haley SmithDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
Ramgopal R MettuDepartment of Computer Science, Tulane University, New Orleans, Louisiana, United States, Tulane University School of Medicine, New Orleans, LA, United States.
Loren GragertDepartment of Medicine, Tulane University School Medicine, New Orleans, LA, United States.
Judith H AberleCenter for Virology, Medical University of Vienna, Vienna, Austria.
Kevin J ZwezdarykDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, United States.
Crystal ZhengDepartment of Medicine, Tulane University School of Medicine, New Orleans, LA, United States.
Jay K KollsDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, United States.
Bronwyn M GunnPaul G. Allen School of Global Health, Washington State University, Pullman, WA, United States.
Amelie E MurrellDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, United States.
Ivy V TrinhDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, United States.
John S SchieffelinDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, United States.
James E Robinson *Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA, United States.
Elizabeth B Norton *Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, United States.

Funding

Tulane University COVID Antibody and Immunity Network (TUCAIN) SupplementU54CA260581 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI ROBINSON, JAMES E · 2020 to 2024
$9.2M
Acquisition of next-generation Orbitrap Eclipse Tribrid Mass Spectrometer systemS10OD032453 · OD · TULANE UNIVERSITY OF LOUISIANA · PI FAN, JIA · 2022 to 2022
$1.4M
NCI NIH HHS U54 CA260581NIH HHS S10 OD032453
6 · The paper itself

Abstract

Introduction: Epitope-specific T cells provide significant long-lived protection afforded by adaptive immunity to SARS-CoV-2 spike. CD4+ T-cell epitope peptides that are generated by non-ATP-dependent antigen-processing proteases bind with modest specificity to MHC class II molecules in the endo-lysosome. Studies document the influence of antigen-presenting cell type, manner of endocytosis, and antigen conformation on the strength of CD4+ T-cell response. Nevertheless, few studies report changes in epitope dominance due to circumstances of antigen exposure, which could shape proteolytic antigen processing in the class-II pathway because conformational domains limit proteolysis or MHCII binding. Methods: Processing of SARS-CoV-2 spike was modeled using limited proteolysis of soluble spike trimer, and the effect of spike conformation on CD4+ T-cell epitope dominance was analyzed using IL-2 Elispots responding to two nine-peptide pools from conformationally stable and unstable regions of spike. Results: Protease-sensitive sites coincided with domain boundaries and other conformationally unstable regions, confirming that structure limits proteolysis. The ratio of CD4+ T-cell response to stable and unstable peptide pools in two non-hospitalized human subjects cohorts distinguished whether exposure was by infection or vaccination. Discussion: Circumstances of exposure to spike, e.g., spike mRNA vaccination or SARS-CoV-2 infection, could influence populations of antigen presenting cells and their levels of activation, resulting in different patterns of spike fragmentation, peptide loading, and T-cell response. Circumstances of exposure also affect spike conformational changes that contribute to distinct dominance patterns. Thus, epitope dominance patterns potentially indicate exposure history, immune imprinting, and potentially the protectiveness of the CD4+ T-cell response.

Indexed as

CD4-Positive T-LymphocytesCOVID-19Epitopes, T-LymphocyteImmunodominant EpitopesSARS-CoV-2Spike Glycoprotein, CoronavirusAntigen PresentationHumansProtein ConformationEpitopes, T-LymphocyteImmunodominant EpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antigen processingfusogenic conformational changeimmunological imprintinginnate to adaptive immune communicationoriginal antigenic sin

Identifiers

PMID42548704
PMCPMC13429665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.